Rocky Mountain Poison and Drug Center, Denver, Colorado 80204, USA.
Pain Med. 2012 Mar;13(3):434-42. doi: 10.1111/j.1526-4637.2012.01327.x. Epub 2012 Feb 2.
Prescription monitoring programs (PMPs) are statewide databases containing prescriber and patient-level prescription data on select drugs of abuse. These databases are used by medical professionals or law enforcement officials to identify patients with prescription drug use patterns indicative of abuse or providers engaging in illegal activities. Most states have implemented PMPs in an attempt to curb prescription drug abuse and diversion. However, assessment of their impact on drug abuse is only beginning. This study aimed to evaluate the relationship between PMPs and opioid misuse over time in two drug abuse surveillance data sources.
Data from the RADARS® System Poison Center and Opioid Treatment surveillance databases were used to obtain measures of abuse and misuse of opioids. Repeated measures negative binomial regression was applied to quarterly surveillance data (from 2003 to mid-2009) to estimate and compare opioid abuse and misuse trends. PMP presence was modeled as a time varying covariate for each state.
Results support an association between PMPs and mitigated opioid abuse and misuse trends. Without a PMP in place, Poison Center intentional exposures increased, on average, 1.9% per quarter, whereas opioid intentional exposures increase 0.2% (P = 0.036) per quarter with a PMP in place. Opioid treatment admissions increase, on average, 4.9% per quarter in states without a PMP vs 2.6% (P = 0.058) in states with a PMP. In addition to the time trend, population and a measure of drug availability were also significant predictors. A secondary analysis that classified PMP based upon ideal characteristic showed consistent though not significant results.
Two observational data sources offer preliminary support that PMPs are effective. Future efforts should evaluate what PMP characteristics are most effective and which opioids are most impacted.
处方监测计划(PMP)是全州范围内的数据库,包含选定滥用药物的处方医生和患者级别的处方数据。这些数据库被医疗专业人员或执法人员用于识别具有滥用药物使用模式的患者或参与非法活动的提供者。大多数州都实施了 PMP,以试图遏制处方药物滥用和滥用。然而,对其对药物滥用影响的评估才刚刚开始。本研究旨在评估两个药物滥用监测数据源中 PMP 与阿片类药物滥用随时间的关系。
使用 RADARS®系统中毒中心和阿片类药物治疗监测数据库的数据,获取阿片类药物滥用和误用的衡量标准。对季度监测数据(2003 年至 2009 年年中)进行重复测量负二项式回归,以估计和比较阿片类药物滥用和误用趋势。将 PMP 存在建模为每个州的时变协变量。
结果支持 PMP 与减轻阿片类药物滥用和误用趋势之间的关联。如果没有 PMP,中毒中心的故意暴露平均每季度增加 1.9%,而有 PMP 的情况下,阿片类药物的故意暴露每季度增加 0.2%(P = 0.036)。没有 PMP 的州,阿片类药物治疗入院人数平均每季度增加 4.9%,而有 PMP 的州则增加 2.6%(P = 0.058)。除时间趋势外,人口和药物可用性的衡量标准也是重要的预测因素。基于理想特征对 PMP 进行分类的二次分析显示,结果一致但不显著。
两个观察性数据源提供了初步支持,表明 PMP 是有效的。未来的工作应评估哪些 PMP 特征最有效以及哪些阿片类药物受到的影响最大。